Yes, an oral glucose tolerance test (OGTT) is strongly recommended for all women with PCOS.
The Endocrine Society Clinical Practice Guideline explicitly recommends using a 75-gram OGTT (with fasting and 2-hour glucose measurements) to screen for impaired glucose tolerance (IGT) and type 2 diabetes in all adolescents and adult women with PCOS 1.
Why OGTT Over Other Tests
The guideline prioritizes OGTT over HbA1c or fasting glucose for several critical reasons:
- Women with PCOS face a 5- to 10-fold increased risk of developing type 2 diabetes, with 30-35% having glucose intolerance and 3-10% having frank diabetes at diagnosis 1
- HbA1c has poor sensitivity for detecting IGT in this population—a 2024 meta-analysis demonstrated that HbA1c ≥6.5% misses 50% of women with type 2 diabetes when compared to OGTT 2
- OGTT better identifies women at risk for cardiovascular disease and gestational diabetes before pregnancy, both critical outcomes for morbidity and mortality 1
- Even non-obese women with PCOS have 10-15% prevalence of IGT, making universal screening essential regardless of BMI 1
Screening Schedule
- Initial OGTT at diagnosis of PCOS
- Rescreening every 3-5 years if normal glucose tolerance 1
- More frequent screening (potentially annually) if central adiposity, substantial weight gain, or symptoms of diabetes develop 1
Alternative Only When Necessary
HbA1c may be considered only if a patient is unable or unwilling to complete an OGTT 1, but this is explicitly a second-line option given its inferior sensitivity.
Clinical Reality vs. Guidelines
Despite clear guideline recommendations, real-world practice falls short. A 2016 survey found that only 7% of obstetrician-gynecologists order OGTTs for PCOS patients, with most using HbA1c (51%) or fasting glucose (42.7%) instead 3. A 2024 study of commercial insurance claims showed that among screened women with PCOS, only 19.24% received the recommended OGTT 4. This represents a significant gap in care that directly impacts early detection of metabolic disease.
Why This Matters for Outcomes
The rationale for aggressive screening centers on preventing progression to diabetes, reducing cardiovascular risk, and preventing gestational diabetes—all of which directly impact morbidity and mortality 5. Women with PCOS show deterioration in glucose tolerance over time 1, making early detection through the most sensitive test (OGTT) essential for timely lifestyle intervention or pharmacotherapy with metformin.
Bottom line: Use the 75-gram OGTT with fasting and 2-hour glucose measurements for all women with PCOS at diagnosis and repeat every 3-5 years. Do not rely on HbA1c or fasting glucose alone, as they will miss a substantial proportion of women with early glucose abnormalities who could benefit from intervention.